Financials
- Fiscal year
- 2024
- Total assets
- €2.5m
- Loss
- -€69,773
- Solvency
- 1.5%
Total assets▼ 3.6%
Net result
20182024
TAMIPHAR
ActiveSummary
The annual accounts of TAMIPHAR for fiscal year 2024 show a net loss of 66% of the equity at the start of that year. The 2024 annual accounts show equity of €36,653 and a net result of -€69,773. Equity is growing by ~12.5% per year across the filed fiscal years. Its solvency ranks better than 14% of 6545 sector peers (fiscal year 2024). The company has been active since 1991 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.0% (low).
Overview
What they do
Retail sale of pharmaceutical products
NACE 47730Warehousing and support activities for transportation NACE 52310
#10 employer in Lasne, Wholesale and retail trade sector3 sites
How big
€2.5mtotal assets 2024
- Staff
- 8.5 FTE
- Equity
- €36,653
- Loss
- -€69,773
Who decides
- Largest shareholder
- BLUESTONE · 50%
- Holdings
- 2
Accounts 63 d overdue0 of 5 deeds read
Why 34- Multiple establishment units- Higher-failure-rate sector- Annual accounts: weaker financial profile- Higher-failure-rate region- Persistent losses- Weak solvency vs sector+ Long track record+ Lower-risk legal formFiled after the deadlineShow the evidence
Checked score
Score 2024
Axes · tick = 2023
Profitability29▼-3
Solvency26▼-3
Growth32▼-20
Track record100
Bankruptcy probability, 12 months
1.0%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €1,000 at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity short (current ratio 0.28 against 0.29 in 2023; short-term debt: 96.7% and cash: 1.8% of total assets), and 98.5% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Nine signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
1.5%
Return on assets
-2.8%
Age of the figures
21 mo
raises risk · Persistent losses
Two consecutive loss-making years (2023 and 2024); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2024Net result per financial year
18192021222324
2018 to 2024 · latest year -€69,773
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 6545 sector peers (2024).
NBB · sector comparisonPosition among 6545 sector peers
Solvency
better than 14%
← weakest
strongest →
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 10-10-2025, 71 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
71 d late
2023
92 d late
2022
221 d late
2021
239 d late
2020
89 d late
2019
122 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 139 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (1)
- Annual accounts filedfiscal year 2024 · full…
- Weakest financial yearnet -€69,773
- Annual accounts filedfiscal year 2023 · full…
Key points
By topic
Board & ownership
- Largest shareholder
- BLUESTONE · 50%
Network & group
- Subsidiaries
- 2
2 subsidiaries
Timeline
- Events
- 14
- Since
- 2016
- 10-10-2025Annual accounts filed
- 31-12-2024Weakest financial year
- 31-10-2024Annual accounts filed
Support & recognitions
- Recognitions
- 1 register
- FASFC
- 3authorised sites
Company details
- Sites
- 3
- Legal form
- Public limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 28-03-1991
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.